NASDAQ:GBT
Delisted
GLOBAL BLOOD THERAPEUTICS Stock News
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'
09:07am, Thursday, 04'th Aug 2022
Shares of Global Blood Therapeutics Inc. GBT, +3.04% were up 34.4% in premarket trading on Thursday after Bloomberg reported that the company is "attracting takeover interest," citing people familiar
Why Global Blood Therapeutics Stock Is Surging After Hours
10:17pm, Wednesday, 03'rd Aug 2022 Benzinga
Global Blood Therapeutics Inc (NASDAQ: GBT) shares are soaring in Wednesday's after-hours session following a report suggesting the company is attracting takeover interest.
According to a Bloomberg r
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
08:05pm, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
02:01pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline
02:01pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline
11:40am, Tuesday, 26'th Jul 2022
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
07:01am, Tuesday, 26'th Jul 2022 GlobeNewswire Inc.
Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease Voxelotor is the first medic
GUERBET : Chiffre d’affaires au 30 juin 2022
03:45pm, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Chiffre d’affaires du 1er semestre 2022
Guerbet: Revenue at June 30, 2022
03:45pm, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
H1 2022 sales
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
12:00pm, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
12:00pm, Wednesday, 13'th Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approxi
GBT Announces New Employment Inducement Grants
08:05pm, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2022, the compensation committee of GBT’s boar
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2022
06:22am, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2022
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
03:47pm, Thursday, 30'th Jun 2022 Zacks Investment Research
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the tr
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
02:52pm, Thursday, 30'th Jun 2022
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the tr
